Fingolimod. Mitsubishi Pharma/Novartis.
نویسنده
چکیده
Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.
منابع مشابه
Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
UNLABELLED Once-daily fingolimod 0.5 mg (FTY720; Gilenya(®), Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that is approved for the treatment of relapsing multiple sclerosis (MS); currently, this includes approval in 13 Latin American countries. However, despite a well-characterized efficacy and safety profile in a large clinical development program, th...
متن کاملSteroid-resistant remitting seronegative symmetrical synovitis with pitting oedema associated with gout treated with etanercept.
Disclosure statement: M.K. has received speaking fees from Eisai, Chugai Pharma, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Janssen Pharma, Astellas Pharma, Takeda Pharma and Abbott Japan. M.T. has received speaking fees from Mitsubishi Tanabe Pharma, Astellas Pharma and Janssen Pharma. M.M. has received speaking fees from Pfizer. S.Y. has received speaking fees from Eisai, Mitsubishi Tana...
متن کاملIstradefylline for Restless Legs Syndrome Associated with Parkinson’s Disease
* To whom correspondence should be addressed. E-mail: [email protected] Editor: Elan D. Louis, Yale University, USA Received: October 16, 2017 Accepted: December 14, 2017 Published: January 8, 2018 Copyright: ’ 2018 Nuermaimaiti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user ...
متن کاملA randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects
Fingolimod is an oral agent approved for the treatment of relapsing forms of multiple sclerosis (MS), which has demonstrated efficacy in Phase III trials in patients with relapsing-remitting MS (RRMS). The present study was designed to assess bioequivalence between a fingolimod Test capsule formulation (Teva Argentina, formerly IVAX Argentina S.A.) and a Reference capsule formulation (Novartis ...
متن کاملThe PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
BACKGROUND Fingolimod (Gilenya) is an oral medication for patients with highly active relapsing-remitting Multiple Sclerosis (RRMS). Clinical trials and post-marketing experience on more than 114,000 patients have established a detailed safety profile. Total patient exposure now exceeds 195,000 patient-years as stated in the last financial report (Dec 2014) of the Novartis Pharma AG, Basel, Swi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- IDrugs : the investigational drugs journal
دوره 8 3 شماره
صفحات -
تاریخ انتشار 2005